Up until MDMA was prohibited in the 1980s, it was being used as adjunct to psychotherapy. In the past 20 years, research into the efficacy of MDMA-assisted psychotherapy has recommenced internationally with one Phase 3 clinical trial now complete and more underway. This presentation will provide an overview of the recent research conducted overseas. It will also provide a glimpse into how these treatments are being examined in Australia and what the future of MDMA-assisted psychotherapy might look like in Australia.
Dr Stephen Bright has worked as a clinically-trained psychologist within the Mental Health & AOD field for the past 20 years. He is currently Senior Lecturer of Drug Studies at Edith Cowan University. In addition to psychedelic science, Stephen conducts research into media reporting of AOD-related issues (as seen in the Daily Telegraph), emerging drug trends and harm reduction. He is an advocate for an evidence-based approach to AOD legislation and has provided oral evidence to parliamentary and coronial inquests. Stephen is a co-founder of Psychedelic Research in Science & Medicine (PRISM), an Australian non-profit research association that develops, initiates, coordinates and supports formal research into mainstream medical applications of psychoactive compounds, known as psychedelics.